GLP1R and diabetes mellitus: SGLT2i and GLP-1 RAs, for example, are already available glucose-lowering medicines that induce modest weight loss and are anticipated to play a larger role in diabetes care in the future, especially given the positive findings of their usage in recent cardiovascular outcome trials.